Trial Profile

Double-Blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-Resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous beta-Blocker or Calcium Channel Blocker.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Aug 2012 Actual patient number changed from 180 to 188 as reported by ClinicalTrials.gov.
12 Jul 2011 New source identified and integrated (European Clinical Trials Database record).
08 Nov 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com